Search

Alliances & partnerships

EHA's approach to policy and regulatory affairs involves collaboration across medical professions and disciplines.

Read more

Recommendation for hematologists in COVID-19 crisis

Recommendations for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in patients with active cancer. It should be taken seriously and managed rigorously without jeopardizing the curative chance of individual cancer patients.

Read more

EHA-EMBL/EBI Computational Biology Training in Hematology

The CBTH 2025 call for applications is now closed.

Read more

Research & Mentoring

One of EHA’s key pillars is investing in future leaders in hematology.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

European Board for Accreditation in Hematology

Current committee members
Peter van den Burg, The Netherlands (Chair and ISBT representative—transfusion medicine)
Michelle Kenyon, United Kingdom (EBMT Nurses Group representative—Specialized Hematology Professional)
Fionnuala Ní Áinle, Ireland (ISTH representative—thrombosis and hemostasis)
Annalisa Ruggeri, Italy (Representative, clinical hematology)
Isabel Sanchez-Ortega, Spain (EBMT representative)
Ana Filipa Marques…

Read more